United States Acute Coronary Syndrome Market Set for Robust Growth with Advancements in Treatment & Rising Cardiovascular Cases 2025 | Top key players - Merck, Novartis, Amgen Inc.

Market Size and Growth:

The Global Acute Coronary Syndrome Market size reached US$ 9.94 billion in 2023 and is expected to reach US$ 14.70 billion by 2031, growing at a CAGR of 5.1% during the forecast period 2024-2031.

The Acute Coronary Syndrome Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Acute Coronary Syndrome market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for growth.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/acute-coronary-syndrome-market?sz

The Acute Coronary Syndrome (ACS) Market refers to the healthcare sector focused on the diagnosis, treatment, and management of conditions caused by sudden, reduced blood flow to the heart, including unstable angina and myocardial infarction. It encompasses pharmaceuticals, medical devices, diagnostics, and therapeutic approaches aimed at reducing morbidity, mortality, and improving patient outcomes globally.

Recent Key Developments of United States (U.S):

Release of the 2025 ACS Management Guideline: The American College of Cardiology (ACC), American Heart Association (AHA), and other societies published an updated guideline for managing ACS. This new guideline emphasizes rapid diagnosis, evidence-based secondary prevention, and incorporates new data on antithrombotic and lipid-lowering therapies. (June 2025)

Upgraded Recommendation for Intracoronary Imaging: The 2025 guideline elevated the recommendation for using intracoronary imaging (like intravascular ultrasound) to guide percutaneous coronary intervention (PCI) to a Class 1 (strong) recommendation. This is a significant change aimed at improving patient outcomes. (May 2025)

Emphasis on Complete Revascularization: The updated guideline provides a strong recommendation for complete revascularization in patients with multivessel ACS. It also recommends that PCI of severe lesions in non-culprit vessels can be performed either during the same procedure or in a staged approach, reflecting new clinical trial data. (May 2025)

Advancements in Antithrombotic and Lipid-Lowering Therapies: The new clinical guidelines highlight the continued importance of dual antiplatelet therapy (DAPT) and high-intensity statins. They also recommend non-statin lipid-lowering agents (like PCSK9 inhibitors) for high-risk patients who don't meet cholesterol targets with statins alone. (May 2025)

Focus on AI and Targeted Therapies in the Pipeline: Market reports from mid-2025 indicate a growing focus on innovative approaches in the ACS pipeline. This includes the development of artificial intelligence (AI)-based triage tools for improved diagnosis and emerging therapies targeting novel pathways, such as factor XIa (FXIa) inhibitors to reduce thrombotic events without increasing bleeding risk. (June-July 2025)

Key Players:

Teva Pharmaceuticals
Dr. Reddy's Laboratories
Boehringer Ingelheim
Johnson & Johnson
Merck
Novartis
Amgen Inc.
AbbVie Inc.
AstraZeneca PLC
GlaxoSmithKline Plc.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=acute-coronary-syndrome-market

Market Segmentation:

By Type: ST-elevation Myocardial Infarction, Non-ST-Elevation Myocardial Infarction, Unstable Angina.

By Drugs: Antithrombotic, Antihypertensive, Statin Drugs.

By End-User: Hospital, Specialty Clinics, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/acute-coronary-syndrome-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Acute Coronary Syndrome market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Acute Coronary Syndrome Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Acute Coronary Syndrome market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Acute Coronary Syndrome Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Acute Coronary Syndrome Market in 2025?
◆ What is the projected growth rate of the Acute Coronary Syndrome Market through 2033?
◆ Who are the key players in the Acute Coronary Syndrome Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.